Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
Nautilus Biotechnology Inc.
NAUT | US
3.13
USD-0.13
-3.85%
NAUT | US
About Nautilus Biotechnology Inc.
Sector
Healthcare
Industry
Biotechnology
Earnings date
30/06/2024
As of date
16/04/2026
Close
3.13
Open
3.24
High
3.28
Low
2.92
Nautilus Biotechnology Inc. a development stage life sciences company engages in creating a platform technology for quantifying and unlocking the complexity of the proteome. It develops Nautilus Platform a proteomics platform that includes end-to-end solution comprised of instruments consumables and software analysis. The company was incorporated in 2016 and is headquartered in Seattle Washington.
View LessNAUT | US
Risk
120.5
Sharpe
2.76
Luna's Score
55/100
Recommendation
Hold
Luna says (NAUT | US)
What's Working
Positive Momentum
Low Debt to Equity (< 0.25)
Low Debt to Asset (< 0.2)
Value Stock (Price to Book < 3)
Strong Sharpe Ratio (> 1.2)
What's not Working
Weakness based on declining price with high volume
Price Below SMA10D
High 6-Month Volatility (>65%)
Smallcap (300M - 2B USD)
High Market Beta (> 0.8)
Volatility Signals
Bearish: Increased Volatility (6-month > 1-month volatility)
Risk Meter
10 days
59.7%1 month
120.5%3 months
108.1%6 months
127.7%Returns
Fundamental Ratios
PE
-
Fwd. PE
-
Price to book
1.53
Debt to equity
0.14
Debt to assets
0.12
Ent. to EBITDA
-2.00
Ent. to rev.
-
PEG
-
Other Fundamentals
EBITDA
-79.42M
MarketCap
391.91M
MarketCap(USD)
391.91M
Div. yield
-
Op. margin
-
Erngs. growth
-
Rev. growth
-
Ret. on equity
-26.53
Short ratio
13.56
Short perc.
2.90
Market Sentiment (SMA and Price signals)
Short-term: Bearish (SMA10D < SMA1M)
Intermediate-term: Bullish (SMA1M > SMA3M)
Long-term: Bullish (SMA6M > SMA12M)
SMAs: Stock Price Trends
Range10D
0.64
Range1M
1.95
Range3M
2.56
Volumes: Market Activity
Rel. volume
1.10
Price X volume
1.51M
Peers
Diversifiers
Industry Comparison
| Parameter | Company | Industry | Indicator |
|---|---|---|---|
| Enterprise to EBITDA | -2.00 | - | Cheaper |
| Ent. to Revenue | - | - | - |
| PE Ratio | - | 41.03 | - |
| Price to Book | 1.53 | 15.55 | Cheaper |
| Dividend Yield | - | - | - |
| Std. Deviation (3M) | 108.09 | - | Riskier |
| Debt to Equity | 0.14 | -1.23 | Expensive |
| Debt to Assets | 0.12 | 0.25 | Cheaper |
| Market Cap | 391.91M | - | Emerging |
